Summarizing current results for patients with brain metastases from HER2 + breast cancer, it can be deduced that current treatment strategies achieve an overall survival of more than 1 year from the time of treatment initiation for tumor dissemination including the brain. This evidence concerns the gene ERBB2 and neoplasm.